Back to Search
Start Over
Impact of lamivudine treatment in late pregnancy on the development of the foetal immune response to hepatitis B virus: a meta-analysis in R with the metafor package.
- Source :
-
Transactions of the Royal Society of Tropical Medicine and Hygiene [Trans R Soc Trop Med Hyg] 2024 Apr 06; Vol. 118 (4), pp. 264-272. - Publication Year :
- 2024
-
Abstract
- Background: Hepatitis B virus (HBV) infection is a worldwide public health burden, especially in Asia and Africa. Concerns were raised that foetal exposure to HBV and antiretroviral therapy (ART) might suppress the innate immune response and reduce the production of hepatitis B surface antibody (HBsAb) in foetuses and infants. We therefore conducted the current study to evaluate the impact of ART on the development of the immune response to HBV in foetuses and infants.<br />Methods: We selected lamivudine instead of telbivudine or tenofovir as the intervention measurement because it was the oldest and most widely used ART during pregnancy and its safety data have been sufficiently documented. A comprehensive search was conducted in eight electronic databases, including four Chinese and four English databases. Studies that met the following eligibility criteria were included: human randomized controlled trials (RCTs); participants in the treatment group were exclusively exposed to lamivudine; participants in the control group were exposed to placebo, no treatment or hepatitis B immunoglobulin; all participants were HBV-positive pregnant women with a high viral load and the main outcome of interest was neonatal HBsAb seropositivity. Data were tabulated and analysed using R software.<br />Results: Nine RCTs were included and analysed. Compared with controls, lamivudine significantly decreased HBsAb seronegativity in the newborn within 24 h after birth (indicating the foetal immune response to HBV). Similar results were noted in infants within 6-7 months after birth and infants within 12 months (indicating the neonatal immune response to HBV vaccine).<br />Conclusions: Lamivudine treatment in late pregnancy boosted the foetal immune response to HBV in utero and enhanced the neonatal immune response to hepatitis B vaccine after birth.<br /> (© The Author(s) 2023. Published by Oxford University Press on behalf of Royal Society of Tropical Medicine and Hygiene.)
- Subjects :
- Humans
Pregnancy
Female
Antiviral Agents therapeutic use
Infant, Newborn
Randomized Controlled Trials as Topic
Fetus drug effects
Fetus immunology
Lamivudine therapeutic use
Pregnancy Complications, Infectious drug therapy
Hepatitis B drug therapy
Hepatitis B immunology
Infectious Disease Transmission, Vertical prevention & control
Hepatitis B virus immunology
Hepatitis B Antibodies blood
Subjects
Details
- Language :
- English
- ISSN :
- 1878-3503
- Volume :
- 118
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Transactions of the Royal Society of Tropical Medicine and Hygiene
- Publication Type :
- Academic Journal
- Accession number :
- 38048279
- Full Text :
- https://doi.org/10.1093/trstmh/trad084